ALKBH5 and hepatocellular carcinoma: The high level of ALKBH5 also impairs m6A modification in PAQR4 mRNA, which then hampers its recognition by IGF2BP1, thus weakening the expression of PAQR4 and inhibiting the activation of the PI3K/AKT pathway to impede the occurrence and development of HCC (26).